Literature DB >> 32477019

Dual-time-point PET/CT study protocol can improve the larynx cancer diagnosis.

Agata Karolina Pietrzak1,2, Joanna Kazmierska1, Andrzej Marszalek3, Pawel Golusinski4, Aleksandra Heydrych1,2, Katarzyna Wiechec5, Witold Cholewinski1,2.   

Abstract

AIM: To evaluate whether the sequential dual-time-point fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (DTP 18F-FDG PET/CT) study improves the differential diagnosis in the larynx.
BACKGROUND: In some cases, the clinical and metabolic similarity of laryngitis and larynx cancer make differential diagnostics difficult when performing standard 18F-FDG PET/CT examinations; therefore, an additional study protocol performance seems to be of reasonable value.
MATERIALS AND METHODS: 90 patients (mean age: 61 ± 11 years, range: 41-84 years): 23 women (mean age: 63 ± 10 years, range: 51-84 years) and 67 men (mean age: 61 ± 11 years, range: 41-80 years) underwent delayed 18F-FDG PET/CT examinations at 60 and 90 min post intravenous injection (p.i.) of the radiopharmaceutical 18F-FDG. We compared the metabolic activity of 90 structures divided into following groups: normal larynx (30 patients), laryngitis (30 lesions) and larynx cancer (30 tumors) with maximal and mean standardized uptake value (SUVmax, SUVmean) and the retention index (RI-SUVmax). We used the receiver operating characteristics (ROC) curve to evaluate the SUVmax cut-off values.
RESULTS: The SUVmax cut-off value at 60 and 90 min p.i. of 2.3 (sensitivity/specificity: 96.4%/100%) and 2.4 (94.2%/100%), respectively, distinguished normal and abnormal metabolic activity in the larynx. When laryngitis and tumors were compared, the SUVmax cut-off values obtained after initial and delayed imaging were 3.6 (87.5%/52.0%) and 6.1 (58.3%/84%), respectively. The RI-SUVmax of 1.3% (71.4%/88.1%) suggested abnormality, while RI-SUVmax of 6.6%, malignant etiology (75.0%/80.0%).
CONCLUSIONS: In this study, the sequential DTP scanning protocol improved the sensitivity and specificity of the PET/CT method in terms of differential diagnosis within the larynx.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  18F fluorodeoxyglucose; Larynx cancer; Positron emission tomography

Year:  2020        PMID: 32477019      PMCID: PMC7251542          DOI: 10.1016/j.rpor.2020.04.013

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  17 in total

Review 1.  ¹⁸F-FDG PET and PET/CT patient preparation: a review of the literature.

Authors:  Devaki Shilpa Surasi; Pradeep Bhambhvani; Jon A Baldwin; Samuel E Almodovar; Janis P O'Malley
Journal:  J Nucl Med Technol       Date:  2014-02-06

2.  Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.

Authors:  Carryn M Anderson; Tangel Chang; Michael M Graham; Michael D Marquardt; Anna Button; Brian J Smith; Yusuf Menda; Wenqing Sun; Nitin A Pagedar; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

3.  Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy.

Authors:  Radovan Vojtíšek; Jiří Ferda; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-17

Review 4.  Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations.

Authors:  Rahul V Parghane; Sandip Basu
Journal:  Semin Nucl Med       Date:  2017-04-19       Impact factor: 4.446

5.  Dual-time-point 18F-FDG PET/CT in the diagnosis of solitary pulmonary lesions in a region with endemic granulomatous diseases.

Authors:  Yu-Erh Huang; Yu-Jie Huang; Mary Ko; Chien-Chin Hsu; Chih-Feng Chen
Journal:  Ann Nucl Med       Date:  2016-08-04       Impact factor: 2.668

Review 6.  Epiglottic masses identified on CT imaging: A case report and review of the broad differential diagnosis.

Authors:  Jonathan Tresley; Efrat Saraf-Lavi; Oleksandr N Kryvenko; Oleksandr Kryvenko; Zoukaa Sargi
Journal:  Neuroradiol J       Date:  2015-06

Review 7.  Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers.

Authors:  Farzan Siddiqui; Min Yao
Journal:  World J Radiol       Date:  2014-06-28

8.  Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?

Authors:  Hussein Rabie Saleh Farghaly; Mohamed Hosny Mohamed Sayed; Hatem Ahmed Nasr; Ahmed Marzok Abdelaziz Maklad
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec

9.  The maximum standardized uptake value increment calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography predicts survival in patients with oral tongue squamous cell carcinoma.

Authors:  Natsuki Yonezawa; Tsutomu Minamikawa; Kazuhiro Kitajima; Yusuke Takahashi; Ryohei Sasaki; Ken-Ichi Nibu; Takahide Komori
Journal:  Nagoya J Med Sci       Date:  2017-02       Impact factor: 1.131

10.  Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study.

Authors:  Do Hyoung Lim; Jai Hyuen Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-04-10
View more
  2 in total

1.  Improved Clinical Workflow for Whole-Body Patlak Parametric Imaging Using Two Short Dynamic Acquisitions.

Authors:  Hui Wang; Ying Miao; Wenjing Yu; Gan Zhu; Tao Wu; Xuefeng Zhao; Guangjie Yuan; Biao Li; Huiqin Xu
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

2.  Comparison of Volumetric Quantitative PET Parameters Before and After a CT-Based Elastic Deformation on Dual-Time 18FDG-PET/CT Images: A Feasibility Study in a Perspective of Radiotherapy Planning in Head and Neck Cancer.

Authors:  Meriem Maajem; Jean-Christophe Leclère; David Bourhis; Valentin Tissot; Nicolas Icard; Laëtitia Arnaud; Romain Le Pennec; Gurvan Dissaux; Dorothy M Gujral; Pierre-Yves Salaün; Ulrike Schick; Ronan Abgral
Journal:  Front Med (Lausanne)       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.